// App-Quantinova.ai

TPS1119 : A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).

Researchers

Presenter

  • Romualdo Barroso-Sousa

Principal Investigators

  • Hao Guo

  • William Thomas Barry

  • Grace Winship

  • Beth Overmoyer

  • Dan G. Duda

  • Sara M. Tolaney

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Progesterone receptor

Drug/Treatment

  • Cabozantinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • Single Arm

  • Single Center

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved